Bombay High Court Prioritizes Patient Safety in Trademark Dispute

The Bombay High Court has issued a crucial ruling emphasizing the importance of clear and distinct trademarks for pharmaceutical products. The case centred on a dispute between Glenmark Pharmaceuticals Ltd. and Gleck Pharma (OPC) Pvt Ltd. over trademarks for anti-diabetes medication. Glenmark, the owner of the trademark "Zita-met," sued Gleck for using the allegedly "deceptively similar" trademark "Xigamet" for their diabetes medication. While both medications contain the drug Metformin, their active ingredients differ. Justice F P Pooniwalla, presiding over the case, granted Glenmark a temporary injunction against Gleck. In his judgment, Justice Pooniwalla acknowledged the expertise of doctors and chemists but stressed that even slight confusion in medication trademarks could have severe consequences. "Physicians, doctors, and chemists are not immune to confusion or mistake," stated the Judge. He pointed out that prescriptions can be difficult to read, and medications are sometimes purchased over the phone, increasing the risk of errors. The Court emphasized a previous Delhi High Court ruling that consumer perception, not the opinion of medical professionals, is paramount when evaluating trademark similarity for pharmaceuticals. Gleck argued that confusion was unlikely given the drugs' prescription nature. However, the Court countered by citing a Supreme Court decision highlighting the alarming trend of Schedule-H drugs (prescription-only medications) being sold over the counter in India. This reality and the potential for misreading prescriptions and phone orders underscored the need for clear brand differentiation. "The average man with average intelligence who goes to buy medicines is going to be confused between the two marks," the Court concluded. This confusion, the Court ruled, posed a potential threat to patient safety, justifying the injunction against Gleck. This case is a stark reminder of trademarks' critical role in safeguarding public health. It emphasizes the need for pharmaceutical companies to select and protect demonstrably distinct trademarks, even for medications with different active ingredients.